Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
REPL Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: February 06, 2026
Report Source: 2026 3rd Quarter Report
Replimune Group Inc. Stock Analysis REPL
United States Health Care Small Cap Report: Replimune Group, Inc. is a clinical-stage biotechnology company. The company is headquartered in Woburn, Massachusetts and currently employs 479 full-time employees. The company went IPO on 2018-07-20. Its proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor-derived antigens and altering of the tumor microenvironment to ignite a systemic response. Its lead product candidate, RP1, is a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF. Its lead indication for its lead product candidate, RP1, is the potential treatment of advanced melanoma. Its pipeline product candidates include RP2 and RP3. The company has designed its RP2 product candidate to express an anti-CTLA-4 antibody-like protein intended to block the inhibition of the immune response.
Read More Replimune Group Inc (REPL) Chart
Key Statistics of Replimune Group Inc (REPL)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$10.88Volume
2.96MP/E Ratio (TTM)
-52 Week Range
Market Cap
431.03MAvg. Volume
6.29MDividend Yield
-Financial Metrics & Statements of Replimune Group Inc (REPL)
FAQ's for Replimune Group Inc (REPL)
- According to Musaffa’s Shariah screening methodology, Replimune Group Inc (REPL) is currently classified as NOT HALAL as of February 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Replimune Group Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Replimune Group Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Replimune Group Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Replimune Group Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Replimune Group Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.